Tech Company Financing Transactions
Seldar Pharma Funding Round
Seldar Pharma secured a $13 million venture capital round on 6/6/2012. Investors included Astellas Venture Capital, InterWest Partners and Sutter Hill Ventures.
Transaction Overview
Company Name
Announced On
6/6/2012
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Part of the proceeds will be used to acquire a bombesin BB2 receptor antagonist for the treatment of irritable bowel syndrome, from Telsar -- another virtual company operated by Drais.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
520 US Hwy. 22 201
Bridgewater, NJ 08807
USA
Bridgewater, NJ 08807
USA
Phone
Website
Email Address
Overview
Drais Pharmaceuticals, Inc. is an ethical pharmaceutical company headquartered in Bridgewater, New Jersey, and dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Donna Tempel
Vice President
Robert Schinagl
VP - Finance
Christopher Del Mastro
Browse more venture capital transactions:
Prev: 6/6/2012: Lending Club venture capital transaction
Next: 6/6/2012: fisoc venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs